{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T23:35:03Z","timestamp":1770507303911,"version":"3.49.0"},"reference-count":14,"publisher":"BMJ","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gut"],"published-print":{"date-parts":[[1995,4]]},"abstract":"<jats:p>This study determined the optimal maintenance dose of omeprazole in reflux oesophagitis. One hundred and ninety three patients rendered asymptomatic and healed after four or eight weeks omeprazole were randomised double blind to 10 mg omeprazole once daily (n = 60 evaluable), 20 mg omeprazole once daily (n = 68), or placebo (n = 62) for one year or until symptomatic relapse. Each omeprazole regimen was superior to placebo in preventing both symptomatic relapse (life table analysis, p &lt; 0.001) and endoscopically verified relapse (p &lt; 0.001). At 12 months, the life table endoscopic remission rates (proportions of patients without grade &gt; or = 2 oesophagitis) were: 50% (95% confidence intervals 34 to 66%) with 10 mg omeprazole once daily, 74% (62 to 86%) with 20 mg omeprazole once daily, and 14% (2 to 26%) with placebo. At 12 months, the life table symptomatic remission rates (proportions of patients asymptomatic or with mild symptoms) were: 77% (64 to 89%) with 10 mg omeprazole once daily, 83% (73 to 93%) with 20 mg omeprazole once daily, and 34% (16 to 52%) with placebo. Both 10 mg and 20 mg omeprazole once daily were effective in prolonging the remission of reflux oesophagitis: 10 mg may be appropriate to start longterm treatment, though the existence of a dose response relation means that 20 mg once daily may be effective in patients for whom 10 mg once daily is suboptimal.<\/jats:p>","DOI":"10.1136\/gut.36.4.492","type":"journal-article","created":{"date-parts":[[2007,9,18]],"date-time":"2007-09-18T17:41:31Z","timestamp":1190137291000},"page":"492-498","source":"Crossref","is-referenced-by-count":64,"title":["Omeprazole 10 mg or 20 mg once daily in the prevention of recurrence of reflux oesophagitis. Solo Investigator Group."],"prefix":"10.1136","volume":"36","author":[{"given":"C M","family":"Bate","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S N","family":"Booth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J P","family":"Crowe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R A","family":"Mountford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P W","family":"Keeling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Hepworth-Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M D","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P D","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[1995,4,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","DOI":"10.1159\/000200521","article-title":"Australian clinical trials of omeprazole in the management of refiux oesophagitis","volume":"47","author":"Dent, J.","year":"1990","unstructured":"Dent J. Australian clinical trials of omeprazole in the management of refiux oesophagitis. Digestion 1990; 47 (suppl","journal-title":"Digestion"},{"key":"ref_2","first-page":"248","article-title":"Prevention of relapse of reflux oesophagitis after endoscopic healing: the efficacy and safety of omeprazole compared with ranitidine","volume":"26","author":"true","year":"1991","unstructured":"Lundell L, Backman L, Ekstrom P, Enander L-K, Falkmer S, Fausa 0, et al. Prevention of relapse of reflux oesophagitis after endoscopic healing: the efficacy and safety of omeprazole compared with ranitidine. Scand 7 Gastroenterol 1991; 26: 248-56."},{"key":"ref_3","first-page":"37","article-title":"Symptomatic assessment and cost effectiveness of treatments for reflux oesophagitis: comparisons of omeprazole and histamine H2-receptor antagonists","volume":"2","author":"Bate, C.M.; Richardson, P.D.I.","year":"1992","unstructured":"Bate CM, Richardson PDI. Symptomatic assessment and cost effectiveness of treatments for reflux oesophagitis: comparisons of omeprazole and histamine H2-receptor antagonists. BrJ Med Econ 1992; 2: 37-48.","journal-title":"BrJ Med Econ"},{"key":"ref_4","first-page":"63","article-title":"Comparison of two dosage regimens of omeprazole - 10 mg once daily and 20 mg weekends - as prophylaxis against recurrence of reflux oesophagitis","volume":"98","author":"Isal, J.P.; Zeitoun, P.; Barbier, P.; Cayphas, J.P.; Carlsson, R.","year":"1990","unstructured":"Isal JP, Zeitoun P, Barbier P, Cayphas JP, Carlsson R. Comparison of two dosage regimens of omeprazole - 10 mg once daily and 20 mg weekends - as prophylaxis against recurrence of reflux oesophagitis. Gastroenterology 1990; 98: A63.","journal-title":"Gastroenterology"},{"key":"ref_5","first-page":"109","article-title":"Omeprazole 10 mg or 20 mg daily for the prevention of relapse in gastroesophageal reflux disease? A double-blind comparative study","volume":"102","author":"Laursen, I.S.; Bondesen, S.; Hansen, J.; Sanchez, G.; Sebelin, E.; Havelund, T.","year":"1992","unstructured":"Laursen IS, Bondesen S, Hansen J, Sanchez G, Sebelin E, Havelund T, et al. Omeprazole 10 mg or 20 mg daily for the prevention of relapse in gastroesophageal reflux disease? A double-blind comparative study. Gastroenterology 1992; 102: A109.","journal-title":"Gastroenterology"},{"key":"ref_6","first-page":"501","article-title":"Does 40 mg omeprazole daily offer additional benefit over 20 mg daily in patients requiring more than 4 weeks of treatment for symptomatic reflux oesophagitis?","volume":"7","author":"Bate, C.M.; Booth, S.N.; Crowe, J.P.; Hepworth-Jones, B.; Taylor, M.D.; Richardson, P.D.I.","year":"1993","unstructured":"Bate CM, Booth SN, Crowe JP, Hepworth-Jones B, Taylor MD, Richardson PDI. Does 40 mg omeprazole daily offer additional benefit over 20 mg daily in patients requiring more than 4 weeks of treatment for symptomatic reflux oesophagitis? Aliment Pharmacol Ther 1993; 7: 501-8.","journal-title":"Aliment Pharmacol Ther"},{"key":"ref_7","first-page":"5","article-title":"A one year model for the cost effectiveness of treating reflux oesophagitis","volume":"2","author":"Bate, C.M.; Richardson, P.D.I.","year":"1992","unstructured":"Bate CM, Richardson PDI. A one year model for the cost effectiveness of treating reflux oesophagitis. BrJr Med Econ 1992; 2: 5-11.","journal-title":"BrJr Med Econ"},{"key":"ref_8","first-page":"148","article-title":"Low dose omeprazole effects on gastric acid secretion in normal man","volume":"11","author":"Hemery, P.; Galmiche, J.P.; Roze, C.; Isal, J.P.; Bruley des Varennes, S.; Lavignolle, A.","year":"1987","unstructured":"Hemery P, Galmiche JP, Roze C, Isal JP, Bruley des Varennes S, Lavignolle A, et al. Low dose omeprazole effects on gastric acid secretion in normal man. Gastroenterol Clin Biol 1987; 11: 148-53.","journal-title":"Gastroenterol Clin Biol"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1136\/gut.25.9.957","article-title":"Optimal dose of oral omeprazole for maximal 24 hour decrease of intragastric acidity","volume":"25","author":"Sharma, B.K.; Walt, R.P.; Pounder, R.E.; De Fa Gomes, M.; Wood, E.C.; Logan, L.H.","year":"1984","unstructured":"Sharma BK, Walt RP, Pounder RE, De Fa Gomes M, Wood EC, Logan LH. Optimal dose of oral omeprazole for maximal 24 hour decrease of intragastric acidity. Gut 1984; 25: 957-64.","journal-title":"Gut"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/BF02090077","article-title":"Variability in individual response to various doses of omeprazole","volume":"39","author":"Savarino, V.; Mela, G.S.; Zentilin, P.; Cutela, P.; Mele, M.R.; Vigneri, S.","year":"1994","unstructured":"Savarino V, Mela GS, Zentilin P, Cutela P, Mele MR, Vigneri S, et al. Variability in individual response to various doses of omeprazole. Dig Dis Sci 1994; 39: 161-8.","journal-title":"Dig Dis Sci"},{"key":"ref_11","first-page":"29","article-title":"Is there such an entity as mild oesophagitis? European J7ournal of","volume":"4","author":"Green, J.R.B.","year":"1993","unstructured":"Green JRB. Is there such an entity as mild oesophagitis? European J7ournal of Clinical Research 1993; 4: 29-34.","journal-title":"Clinical Research"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"94","DOI":"10.2165\/00019053-199303020-00002","article-title":"Clinical and economic factors in the selection of drugs for gastroesophageal reflux disease","volume":"3","author":"Bate, C.M.; Richardson, P.D.I.","year":"1993","unstructured":"Bate CM, Richardson PDI. Clinical and economic factors in the selection of drugs for gastroesophageal reflux disease. Pharmaco Economics 1993; 3: 94-9.","journal-title":"Pharmaco Economics"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/0016-5085(94)90532-0","article-title":"A comparison of omeprazole and ranitidine in the prevention of recurrence of benign oesophageal stricture","volume":"107","author":"Smith, P.M.; Kerr, G.D.; Cockel, R.; Ross, B.A.; Bate, C.M.; Brown, P.","year":"1994","unstructured":"Smith PM, Kerr GD, Cockel R, Ross BA, Bate CM, Brown P, et al. A comparison of omeprazole and ranitidine in the prevention of recurrence of benign oesophageal stricture. Gastroenterology 1994; 107: 1312-8.","journal-title":"Gastroenterology"},{"key":"ref_14","first-page":"623","article-title":"Regression of columnar lined (Barrett's) oesophagus with continuous omeprazole therapy","volume":"7","author":"Gore, S.; Healey, C.J.; Sutton, R.; Eyre-Brook, I.A.; Gear, M.W.L.; Shepherd, N.A.","year":"1993","unstructured":"Gore S, Healey CJ, Sutton R, Eyre-Brook IA, Gear MWL, Shepherd NA, et al. Regression of columnar lined (Barrett's) oesophagus with continuous omeprazole therapy. Aliment Pharmacol Ther 1993; 7: 623-8.","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Gut"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/gut.36.4.492","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T05:50:11Z","timestamp":1757310611000},"score":1,"resource":{"primary":{"URL":"https:\/\/gut.bmj.com\/lookup\/doi\/10.1136\/gut.36.4.492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1995,4]]},"references-count":14,"journal-issue":{"issue":"4","published-online":{"date-parts":[[1995,4,1]]},"published-print":{"date-parts":[[1995,4]]}},"alternative-id":["10.1136\/gut.36.4.492"],"URL":"https:\/\/doi.org\/10.1136\/gut.36.4.492","relation":{},"ISSN":["0017-5749","1468-3288"],"issn-type":[{"value":"0017-5749","type":"print"},{"value":"1468-3288","type":"electronic"}],"subject":[],"published":{"date-parts":[[1995,4]]}}}